april findings published journal clinical psychopharmacology claimed atypical antipsychotic aripiprazole abilify effective add treatment depression i heartily disagreed study conclusions noting patient rated depression measure demonstrate advantage placebo inconvenient result authors tried explain away unimportant i also pointed study design biased favor abilify study design patients initially assigned receive antidepressant plus placebo eight weeks failed respond treatment assigned abilify antidepressant placebo antidepressant responded initial weeks eliminated study already established antidepressant placebo work people yet assigned treatment weeks treatment compared assigned antidepressant abilify antidepressant placebo group started huge disadvantage already established respond well treatment regimen wonder abilify came top albeit modest margin analogy group students assigned tutored tutor regarding math students tutored weeks students whose math skills improve sent merry way leaves students improve tutor tutelage tutor comes along tutor students tutor sticks tutor students somewhat better tutor students math test weeks later tutor better tutor really fair comparison tutor tutor commenters agreed take matter others two letters editor published latest journal clinical psychopharmacology raised concerns study alexander tsai ucla wrote concerned advantage abilify small points montgomery asberg depression rating scale study design biased favor abilify agreeing earlier point dr bernard carroll wrote letter advantage abilify placebo small advantage patient rated measure due notable side effect profile abilify clinical raters could likely distinguish patients taking abilify taking placebo could biased ratings thus questions study truly double blind authors report whether occurrence several side effects common abilify placebo dr carroll calculated akathisia fatigue restlessness insomnia significantly common abilify wondered authors include data report authors note relationship akathisia severe restlessness tension suicide concerning given abilify produces akathisia droves defense robert berman bristol myers squibb wrote back defend study points impressive noting abilify outperform placebo self report measure trial wrote may due lower sensitivity measure drug failure blame rating scale instead people bms picked scale give results like suddenly poor measurement depression i bet dr berman would complained instrument yielded results favor abilify adverse events reporting adverse events well perfectly good explanation hidden somewhere clearly reported rates spontaneously reported treatment emergent events occurred rate greater treatment group study designed collect adverse events systematic manner statistical comparison treatment groups appropriate let me get straight discussed spontaneously reported events would refer events reported patients without much questioning everyone knows spontaneous reports joke side effects spontaneously reported based spontaneous report rate sexual side effects ssri quite low bother ask people taking ssris questions sexual functioning rates sexual problems increase drastically dr berman goes write suicide related adverse events reported study keep mind study investigators asking events may accurate say nobody committed suicide study nobody tracking suicidal ideation unless patients reported problems yes suicidal ideation covered little bit measures used study systematic assessment would helpful give authors credit least include couple measures extrpyramidal symptoms gathered akathisia happened patients yikes saying study designed collect adverse event data systematic manner frightening adverse event collection systematic authors writing study report adverse events generally mild moderate meaningless ca say adverse event data collected sort systematic manner also say study safe authors claim paper definition duplicitous case authors reported several adverse events significantly likely occur abilify placebo rather making ridiculous claim comparing adverse event rates treatment placebo appropriate dr berman address less point benefit abilify placebo also real explanation address concerns dr tsai myself noted study design biased favor abilify kudos dr caroll dr tsai taking time write excellent letters addressed quite problematic issues study every time i see commercial pimping abilify depression i cringe good know people medical community seeing weak research supports use abilify antidepressant citation offending study ronald marcus et al efficacy safety aripiprazole adjunctive therapy major depressive disorder journal clinical psychoopharmacology